Breaking News, Collaborations & Alliances

Altimmune and CDMO Vigene Enter COVID-19 Vax Pact

Ink manufacturing agreement for AdCOVID single dose intranasal vaccine candidate.

By: Contract Pharma

Contract Pharma Staff

Altimmune has entered into an agreement with Vigene Biosciences to manufacture AdCOVID, Altimmune’s single-dose intranasal vaccine candidate for COVID-19. Vigene, a Rockville, MD-based contract development and manufacturing organization (CDMO), specializes in viral vectors and will deploy its capabilities to manufacture AdCOVID. Following recent positive pre-clinical data, Altimmune plans to start a Phase 1 clinical trial of AdCOVID in Q4 2020.   “Vigene is a fantastic partner to advance AdCOVID...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters